CSIMarket
 
Biohaven Ltd   (BHVN)
Other Ticker:  
 
 
Price: $46.1800 $-1.13 -2.389%
Day's High: $48 Week Perf: -2.24 %
Day's Low: $ 44.39 30 Day Perf: 2.69 %
Volume (M): 1,210 52 Wk High: $ 50.68
Volume (M$): $ 55,896 52 Wk Avg: $25.66
Open: $47.20 52 Wk Low: $12.35



 Market Capitalization (Millions $) 3,155
 Shares Outstanding (Millions) 68
 Employees 274
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -765
 Cash Flow (TTM) (Millions $) 75
 Capital Exp. (TTM) (Millions $) 3

Biohaven Ltd
Biohaven Ltd is a clinical-stage biopharmaceutical company that is focused on developing and commercializing drugs for the treatment of neurological and neuropsychiatric disorders. The company was founded in 2013 and is headquartered in New Haven, Connecticut.

Biohaven's mission is to deliver breakthrough, innovative therapies to patients suffering from neurological and neuropsychiatric disorders who have unmet medical needs. The company's key areas of research and development (R&D) include migraine and other headaches, spinocerebellar ataxia, Alzheimer's disease, and anxiety disorders.

Migraine and Headache Disorders:
Biohaven has developed several products that are designed to target different aspects of migraine and headache disorders. The company's lead drug candidate, Rimegepant, is a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist that has demonstrated efficacy in clinical studies for the acute treatment of migraine. Biohaven is also developing other CGRP receptor antagonists, including BHV-3500 and BHV-0223, and a glutamate modulator, Troriluzole, for the prevention of migraine and related disorders.

Spinocerebellar Ataxia:
Spinocerebellar ataxia (SCA) is a group of genetic disorders that affect the coordination and movement of the body. Biohaven is developing a drug candidate, Troriluzole, which is designed to target the underlying pathology of SCA by modulating the levels of glutamate in the brain. Troriluzole has demonstrated potential benefits in preclinical models of multiple SCAs, and Biohaven is currently conducting clinical trials to evaluate its safety and efficacy in patients with SCA.

Alzheimer's Disease:
Alzheimer's disease is a neurodegenerative disorder that affects memory, cognitive function, and behavior. Biohaven is developing a drug candidate, Verdiperstat, which is a small molecule inhibitor of myeloperoxidase (MPO), an enzyme that is involved in the inflammation associated with Alzheimer's disease and other neuroinflammatory conditions. Biohaven is currently evaluating Verdiperstat in a Phase 2/3 clinical trial for the treatment of Alzheimer's disease.

Anxiety Disorders:
Biohaven is also developing a drug candidate, Troriluzole, for the treatment of anxiety disorders. Troriluzole is a glutamate modulator that has demonstrated potential benefits in preclinical models of anxiety and depression. Biohaven is currently conducting clinical trials to evaluate its safety and efficacy in patients with generalized anxiety disorder.

Biohaven's R&D efforts are supported by a strong intellectual property portfolio, which includes patents covering its drug candidates and their methods of use. The company has a team of experienced scientists, researchers, and clinicians who are dedicated to advancing its pipeline of therapies and bringing them to market as quickly and efficiently as possible.

Overall, Biohaven is a dynamic biopharmaceutical company that is focused on developing innovative therapies to address significant unmet medical needs in neurological and neuropsychiatric disorders. With its talented team, strong pipeline of drug candidates, and commitment to improving the lives of patients, Biohaven is well-positioned to be a leader in its field.


   Company Address: c/o Biohaven Pharmaceuticals, Inc. New Haven 6510 CT
   Company Phone Number: 404-0410   Stock Exchange / Ticker: NYSE BHVN
   BHVN is expected to report next financial results on March 22, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Biohaven Ltd

Biohaven Ltd's Operating Deficit of $-110.547 Million Raises Concerns for Investors and Stakeholders in Q3 2023



The Major Pharmaceutical Preparations sector is closely analyzing Biohaven Ltd's recently released financial results for the third quarter of 2023. With an operating deficit of $-110.547 million and no specified revenue, investors and stakeholders are eager to understand the implications for the company moving forward. By comparing these results with previous quarters and examining the CEO's strategic approach, we can better anticipate the potential impact on Biohaven Ltd's future prospects.
Quarterly Performance and Revenue Context:
For the July to September 2023 period, the company reported an operating deficit of $-110.547 million, without disclosing any revenue figures. However, to gain some perspective, it is worth noting the correlation with the third quarter of 2022 when Biohaven Ltd experienced an operating deficit of $-67.637 million. This data suggests that the financial performance of the company has worsened in recent quarters.

Biohaven Ltd

Shock Drop in Biohaven Ltd Revenue: Fiscal Interval Ends in Deficit

Biohaven Ltd, a pharmaceutical company, recently released its financial results for the fiscal interval closing June 30, 2023. Despite incurring a loss of $-1.32 per share, it shows significant improvement compared to the previous year, where the loss per share was $-6.21. Moreover, Biohaven Ltd was able to reduce its deficit from $-1.03 per share in the preceding reporting season.
Although revenues remained stagnant at $0.00 million, they saw a significant drop from $215.08 million in the same reporting season last year. Sequentially, there was no change in revenue.

Biohaven Ltd

Biohaven Ltd Surpasses Expectations with Impressive First Quarter 2023 Financial Results

Biohaven Ltd Sees Improvements in First Quarter 2023 Financial Results
Biohaven Ltd, the New Haven-based clinical stage biopharmaceutical company, has reported an improvement in its first quarter 2023 financial results, with a decrease in loss per share and an increase in income per share. The company reported a loss of $-1.03 per share, which is a significant decrease from $-2.97 per share from the previous year. Additionally, income per share has improved from $-11.21 per share from the previous reporting period.
While the company's revenue remained unaffected at $0.00 million, the revenue in the same reporting period a year ago was $318.85 million. However, comparing sequentially from the previous reporting period, the revenue remained unchanged.
In the first quarter of 2023, Biohaven Ltd reported a net loss of $-70.492 million, which is a significant improvement from a deficit of $-116.897 million in the same reporting period a year ago.
These financial results have given Biohaven Ltd a positive start for the year and show that the company is moving in the right direction. The biopharmaceutical company has been working on developing innovative therapies for neurological and neuropsychiatric diseases.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright Š 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com